A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

NCT04304040 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Lymphoma Recurrent
B-cell Lymphoma Refractory

Interventions

DRUG: Orelabrutinib
DRUG: Recombinant humanized monoclonal antibody MIL62 injection

Sponsor

Beijing InnoCare Pharma Tech Co., Ltd.